Company Directory

Automated chiral chemistry platform for small molecule drug discovery

LCC Technologies is a drug discovery company providing biopharma partners with access to its platform, which combines a proprietary billion-scale virtual chiral library with AI-driven design and automated high-throughput synthesis. The platform delivers stereodefined, sp3-rich building blocks and drug-like compounds across target classes including kinases, GPCRs, and deubiquitinases. LCC operates as the UK arm of XtalPi, a global AI and robotics-driven R&D platform.

AI platform engineering molecular glue drugs for undruggable targets

Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack conventional drug-binding sites. The platform integrates machine learning, physics-based molecular modelling, and iterative experimental validation. Lead programmes are focused on inflammatory and neuroinflammatory diseases.

Chemistry-led CRO and CDMO for pharmaceutical and diagnostics R&D

High Force Research is an independent chemistry CRO and CDMO providing synthetic chemistry, process development, and GMP manufacturing services to the pharmaceutical, biotech, and diagnostics industries. Services span route design, complex synthesis, scale-up, and analytical development through to regulatory-grade manufacture of APIs and intermediates. Capabilities include nucleoside chemistry, PROTAC synthesis, peptide chemistry, and imaging agent development. The company operates MHRA-certified GMP laboratories in Bowburn, Durham, with a dedicated R&D hub at NETPark, Sedgefield.

Integrated contract drug discovery from Cambridge and India

o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology, DMPK, and non-GMP scale-up, supporting hit-to-lead optimisation through to IND-enabling studies. The company works across small molecule, PROTAC, peptide, and fragment-based modalities. The broader o2h group encompasses venture investment, a proprietary therapeutics pipeline, co-working laboratory space, and a technology arm.

Phenotypic screening platform for targeted protein degradation drug discovery

PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets. The platform systematically unmasks cryptic binding sites across the human proteome and links them to therapeutic functions in a live-cell context, enabling the discovery of molecular glue degraders and other targeted protein degradation modalities. The company focuses on oncology and inflammatory disease, working with academic and pharmaceutical partners to advance novel degrader therapeutics.

Small molecule protein degraders targeting oncology and CNS disease

Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small molecules, addressing limitations of existing degrader technologies. Current programmes target disease-relevant proteins in oncology and central nervous system diseases where existing treatments are inadequate.

Precision oncology drug discovery via targeted protein degradation

Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its pipeline is built on cancer biology originating from the University of Oxford, matched to molecularly defined patient populations to address unmet clinical need.

Targeted protein degradation platform for neurodegenerative disease

TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins. The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two decades at the MRC Laboratory of Molecular Biology and UK Dementia Research Institute at Cambridge. The company's pipeline targets neurodegenerative and inflammatory disorders including Alzheimer's and Huntington's disease.

Tunable covalent chemistry platform for neurodegenerative disease

Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease. Its platform combines tunable covalent chemistry with targeted protein degradation, using monovalent small molecules that form durable bonds with disease-driving proteins to produce orally bioavailable, CNS-accessible degraders with improved selectivity. Dunad has operations in Cambridge, UK and Cambridge, Massachusetts, and entered a strategic collaboration with Novartis in 2021.

Next-generation targeted protein degradation therapeutics

Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling improved CNS penetration and wider target scope. Lead programmes target oncology indications including acute myeloid leukaemia, with neurodegenerative diseases as a second therapeutic pillar.

E3 ligase inhibitors stabilising tumour suppressor proteins

Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune indications. The lead programme targets E6AP, an E3 ligase that destabilises the p53 tumour suppressor in HPV-positive head and neck cancer. A development candidate is expected to be announced in 2026.